Gapping down
In reaction to earnings/guidance:
- CVGW -15.6%, KMX -2%
Other news:
- VRTV -20.5% (expands previously announced restructuring plan)
- VERO -16.1% (stock offering)
- BCRX -8.4% (provides update on Galidesivir Program)
- CCXI -7.9% (provides topline results from Accolade trial of Avacopan)
- XCUR -6.7% (files for $150 mln mixed securities shelf offering)
- KNSL -4.9% (to be added to S&P MidCap 400)
- RYTM -2.8% (announce results from a pivotal Phase 3 clinical trial evaluating setmelanotide for the treatment of insatiable hunger and severe obesity in individuals with Bardet-Biedl syndrome (BBS) or Alström syndrome)
- PUMP -1% (new COO)
- OSUR -0.8% (FDA requests more info on its SARS-CoV-2 antibody test),
Analyst comments:
- NTLA -1.3% (downgraded to Neutral from Outperform at Robert W. Baird)